Gaëlle Clermont currently serves as Scientific Director for Namsa Lyon. She has a 15 years’ experience in the medical device industry accelerating research and bringing innovative devices to market. She has supported the development and regulatory approval of numerous devices, combination products and new biotechnologies through pre-clinical evaluation of their safety, performance and efficacy. Gaëlle has directed many researches and pre-clinical studies in the field of cardiology, orthopedics, gastroenterology, dental, wound healing, general surgery, drug delivery…
Gaëlle is a Doctor in Pharmaceutical Sciences, and holds a Ph.D. in Cardiovascular Pharmacology from the University of Burgundy, as well as a Degree in Medical Device and Biological Products Regulation from the University of Paris.
Established in 1967, NAMSA was the first independent company in the world to focus solely on testing medical device materials for safety. Today we have a physical presence in 8 countries on 4 continents and over 1,000 dedicated professionals, and our mission remains, as it has been for 50 years, to make a scientific contribution to every medical device in the world.
NAMSA has progressed beyond a Contract Research Organization (CRO) and into, what we call, a Medical Research Organization (MRO); an organization that not only translates great ideas into great medical products, but allows us to leverage our global knowledge and experience to help Clients in any phase of the product development life cycle bring their product to market, anywhere in the world.
NAMSA offers services from Consulting to Testing to Clinical throughout every stage of the medical device development life cycle. The NAMSA team has extensive knowledge and experience in most therapeutic areas in the medical device space.
Connect with Gaëlle Clermont
Scientific Director, NAMSA